Clinical Scorecard: Correlation of Rv0191 and Rv3008 Efflux Pump Gene Overexpression with Pyrazinamide Resistance in Multidrug-Resistant Mycobacterium tuberculosis: A Multi-Center Investigation

At a Glance

Key Highlights

• Approximately 10 million people infected with tuberculosis globally in 2023.
• Resistance to pyrazinamide (PZA) linked to mutations and efflux pump overexpression.
• Significant association between Rv0191/Rv3008 expression and PZA resistance.
• Study involved 40 clinical isolates from Khuzestan and Khorasan provinces in Iran.
• PZA can reduce treatment duration from 12 months to 6 months.

Guideline-Based Recommendations

Diagnosis

Management

• Monitor efflux pump gene expression in relation to drug resistance.
• Consider individualized treatment plans based on resistance profiles.

Monitoring & Follow-up

• Regular assessment of drug susceptibility and gene expression levels.
• Implement routine follow-up for treatment efficacy.

Risks

Patient & Prescribing Data

PZA resistance mechanisms include pncA mutations and efflux pump overexpression; consider alternative therapies for resistant cases.

Clinical Best Practices

• Conduct regular drug susceptibility testing for accurate treatment planning.
• Consider alternative resistance mechanisms in PZA-resistant cases, including genetic testing.

References

• World Health Organization
• Multidrug-resistant tuberculosis definition